Preview – CDR101


CDR101 is a trispecific next-generation BCMA targeting therapy for the treatment of relapsed/refractory multiple myeloma (RRMM). Multiple myeloma remains incurable and existing therapies are associated with significant shortcomings in terms of durability of response in RRMM. Response duration has improved beyond 12 months Progression Free Survival with a recently approved BCMA targeting cell therapy; however, manufacturing remains a significant challenge. Off-the-shelf bispecific BCMAxCD3 targeting therapies have shown good efficacy but median time to relapse is limited to under 12 months.

Preclinical results for CDR101 have shown it to be up to 100 times more potent in vitro and in vivo than existing bispecifics in clinical development without inducing PD-L1-related cytotoxicity. In vivo and patient ex vivo data presented at ASH2021 show full tumor eradication and longer response compared to BCMA targeting bispecific antibodies. CDR101 has the potential to be a novel off-the-shelf therapeutic approach offering more durable response and the prospect of higher cure rates in MM. CDR101 has excellent drug-like properties with high stability and CHO-based production yield.